BioSpace News Archive

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report results for the fourth quarter and full year ended December 31, 2019 and provide a business update on Thursday, March 12, 2020

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 and will host a conference call that same day at 4:30 PM ET,

Recordati Rare Diseases, Inc., a biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities in the U.S., today announced the transfer of U.S. marketing rights to SIGNIFOR® (pasireotide) injection and SIGNIFOR LAR® (pasireotide) for injectable suspension.

Divisional name and purpose align with expanded capabilities around performance, protection, education, and compliance

MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and twelve-months ended December 31, 2019.

resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual Leerink Partners Global Healthcare Conference in New York City on Thursday, February 27, 2019 at 10:00 AM ET.

VBL Therapeutics (Nasdaq: VBLT) today announced the launch of a phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, in the treatment of metastatic colorectal cancer.